Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 29.
doi: 10.1111/bph.17420. Online ahead of print.

Psilocybin as a novel treatment for chronic pain

Tate Askey  1 , Reena Lasrado  2 , Maria Maiarú  1 , Gary J Stephens  1
Affiliations
Review

Psilocybin as a novel treatment for chronic pain

Tate Askey et al. Br J Pharmacol. .

Abstract

Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti-nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co-morbid with pain. This review primarily explores the utility of preclinical animal models in investigating the potential of psilocybin as an anti-nociceptive agent. Initial studies involving psilocybin in animal models of neuropathic and inflammatory pain are summarised, alongside areas where further research is needed. The potential mechanisms of action, including targeting serotonergic pathways through the activation of 5-HT2A receptors at both spinal and central levels, as well as neuroplastic actions that improve functional connectivity in brain regions involved in chronic pain, are considered. Current clinical aspects and the translational potential of psilocybin from animal models to chronic pain patients are reviewed. Also discussed is psilocybin's profile as an ideal anti-nociceptive agent, with a wide range of effects against chronic pain and its associated inflammatory or emotional components.

Keywords: neuropathic pain; neuroplasticity; nociplastic pain; psilocybin; psychedelic drugs; serotonergic signalling.

PubMed Disclaimer

References

REFERENCES

    1. Abe, K., Kato, G., Katafuchi, T., Tamae, A., Furue, H., & Yoshimura, M. (2009). Responses to 5‐HT in morphologically identified neurons in the rat substantia gelatinosa in vitro. Neuroscience, 159, 316–324. https://doi.org/10.1016/j.neuroscience.2008.12.021
    1. Aghajanian, G. K., & Hailgler, H. J. (1975). Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors. Psychopharmacology Communications, 1(6), 619–629. PMID: 1063421
    1. Aghajanian, G. K., & Marek, G. J. (1999). Serotonin, via 5‐HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Research, 825(1–2), 161–171. https://doi.org/10.1016/s0006-8993(99)01224-x
    1. Agrawal, M., Richards, W., Beaussant, Y., Shnayder, S., Ameli, R., Roddy, K., Stevens, N., Richards, B., Schor, N., Honstein, H., Jenkins, B., Bates, M., & Thambi, P. (2024). Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer, 130, 1137–1146. https://doi.org/10.1002/cncr.35010
    1. Aira, Z., Buesa, I., Salgueiro, M., Bilbao, J., Aguilera, L., Zimmermann, M., & Azkue, J. J. (2010). Subtype‐specific changes in 5‐HT receptor‐mediated modulation of C fibre‐evoked spinal field potentials are triggered by peripheral nerve injury. Neuroscience, 168, 831–841. https://doi.org/10.1016/j.neuroscience.2010.04.032

LinkOut - more resources